Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada

Evommune (NYSE:EVMN)‘s stock had its “outperform” rating reiterated by equities research analysts at Royal Bank Of Canada in a report issued on Friday,Benzinga reports. They currently have a $48.00 price target on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 88.18% from the company’s previous close.

EVMN has been the subject of several other reports. Clear Str upgraded shares of Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Evercore restated an “outperform” rating and issued a $55.00 price target on shares of Evommune in a research report on Tuesday, February 10th. Weiss Ratings began coverage on shares of Evommune in a research report on Tuesday, February 3rd. They issued a “sell (e)” rating for the company. The Goldman Sachs Group upgraded shares of Evommune to a “buy” rating in a research report on Wednesday, January 7th. Finally, Morgan Stanley restated an “overweight” rating and issued a $54.00 price target on shares of Evommune in a research report on Wednesday, February 18th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Evommune currently has an average rating of “Buy” and a consensus target price of $48.43.

Evommune Stock Performance

Shares of NYSE:EVMN opened at $25.51 on Friday. The company has a market cap of $918.80 million and a P/E ratio of -3.16. The company has a 50 day moving average of $24.69. Evommune has a one year low of $13.89 and a one year high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Institutional Investors Weigh In On Evommune

Several large investors have recently modified their holdings of EVMN. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Evommune during the fourth quarter worth $34,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Evommune during the fourth quarter worth $179,000. XTX Topco Ltd acquired a new stake in shares of Evommune during the fourth quarter worth $321,000. Oxford Asset Management LLP acquired a new stake in shares of Evommune during the fourth quarter worth $335,000. Finally, State Street Corp acquired a new stake in shares of Evommune during the fourth quarter worth $539,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.